Professor Peter Ebeling is Chief Investigator in a collaborative study on whether teriparatide reverses osteonecrosis in patients with cancer.
Osteonecrosis (ONJ) is a debilitating side-effect of some chemotherapy causing an area of exposed bone in the jaw region that does not heal.
Professor Peter Ebeling and Dr Ie-Wen Sim are conducting a randomized controlled trial of teriparatide injections to determine whether there is stimulation of bone remodelling and resolution of ONJ.
This project has been awarded an NHMRC project grant of $346,175 and will be administered through the University of Melbourne.
Image credit: Borgioli et al. Ther Clin Risk Manag. 2009; 5: 217–227.